Regulatory expectations for patient input in drug development have shifted from aspiration to documented methodology across three major jurisdictions.
News|Webcasts|October 11, 2024
A New Approach to Global Participant Payments
Author(s)IQVIA
Webinar Date/Time: Tuesday, November 5th, 2024 Option 1: 10am EST | 7am PST | 3pm GMT | 4pm CET Option 2: 1pm EST | 10am PST | 6pm GMT | 7pm CET
Discover how to handle participant payments in global studies with ease. Join us to learn practical tips and new strategies for managing payments across different countries.
Register Free:
Join IQVIA Technologies to explore the intricacies of participant payments in global studies. As trials continue to grow in complexity and scale, understanding these global intricacies — including country-specific regulatory nuances — is crucial. Together, we’ll dig into the details of paying participants in several notoriously challenging countries, discuss best practices to navigate these country-specific challenges and introduce a new approach to managing participant payments.
Three key take-aways
- Discuss the complexities of managing participant payments in global studies.
- Review country-specific challenges and gain insights into effective methods to manage participant payments around the world.
- Explore a new approach to providing participant payments that addresses global complexities.
Speaker:
Zahiah Gueddar
Senior Director, Commercialization
IQVIA Technologies
Zahiah Gueddar leverages over 17 years of diverse industry expertise encompassing delivery, finance, operational effectiveness and the commercial sector. Gueddar offers invaluable insight into the challenges encountered by sponsors, CROs, sites and patients. In her role leading IQVIA’s financial technology offerings, she serves as an innovative partner for clients seeking transformative outcomes and growth opportunities. Known as a strategic thinker and problem solver, Gueddar is responsible for driving growth and differentiation, product go-to market and ensuring innovative and competitive offerings. Gueddar is based in Southern California and is a graduate of San Diego State University.
Register Free:
Related to this article
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
Participant engagement depends more on clarity and understanding than on gamification or incentives, requiring engagement embedded into trial workflows as a core design component rather than a peripheral consideration
In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, shares what she expects to be at the center of the conversation—from building trust between patients and sites to where AI may and may not have a role in that relationship.
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
Why clinical development’s next AI bottleneck is not the model, but the system around it.
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, outlines what it takes to move beyond transactional engagement and treat patient advocacy organizations as long-term partners in the science and the care.